LAMEA Cancer Immunotherapy Market By Technology (Monoclonal Antibodies, Cytokines & Immunomodulators), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer), End User (Hospitals, Clinics)

The Latin America, Middle East and Africa Cancer Immunotherapy Market would witness market growth of 15.5% CAGR during the forecast period (2018 – 2024).  Cancer immunotherapy is the type of cancer treatment helping the immune system fight cancer. There are various kinds of cancer immunotherapies used and they are monoclonal antibody, therapeutic cancer vaccines, checkpoint inhibitors, cytokines, and others. Growing patient population that is suffering from different types of cancer such as lung cancer, breast cancer, ovarian cancer, and other cancers are the factors that drive the global cancer immunotherapy market. Additionally, growing geriatric population and governmental contribution to healthcare expenditure are some other factors that add to the market growth.

Click Here For Free Insights

Based on technology, the market is segmented into Monoclonal Antibodies, Cytokines & Immunomodulators and other technology. Based on application, the market is segmented into Lung cancer, Breast cancer, Colorectal, Prostate cancer, Head & Neck cancer and other application. Based on end user the market is segmented into Hospitals, Clinics and other end user.

Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca, Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Bayer Ag, Immunomedics Inc., Novartis AG, F. Hoffmann-La Roche Ltd

Scope of the Study

Market Segmentation:

 By Technology

• Monoclonal Antibodies,
• Cytokines & Immunomodulators
• Other technology

By Application

•  Lung cancer
•  Breast cancer
• Colorectal
•  Prostate cancer
• Head & Neck cancer
• Other application.

By End User

• Hospitals
• Clinics
• Other End User

By Country

• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Companies Profiled

• AstraZeneca
• Amgen Inc.
• Eli Lilly and Company
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Bayer Ag
• Immunomedics Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd

Chapter 1.    Market Scope & Methodology
1.1    Market Definition
1.2    Objectives
1.3    Market Scope
1.4    Segmentation
1.4.1    LAMEA Cancer Immunotherapy Market, by Technology
1.4.2    LAMEA Cancer Immunotherapy Market, by Application
1.4.3    LAMEA Cancer Immunotherapy Market, by End User
1.4.4    LAMEA Cancer Immunotherapy Market, by Geography
1.5    Methodology for the research
Chapter 2.    Market Overview
2.1    Introduction
2.2    Key Factors Impacting the Market
2.2.1    Market Drivers
2.2.2    Market Restraints
Chapter 3.    LAMEA Cancer Immunotherapy Market by Technology
3.1.1    LAMEA Monoclonal Antibodies Cancer Immunotherapy Market by Country
3.1.2    LAMEA Cytokines & Immunomodulators Cancer Immunotherapy Market by Country
3.1.3    LAMEA Other Technology Cancer Immunotherapy Market by Country
Chapter 4.    LAMEA Cancer Immunotherapy Market by Application
4.1.1    LAMEA Cancer Immunotherapy Lung Cancer Market by Country
4.1.2    LAMEA Cancer Immunotherapy Breast Cancer Market by Country
4.1.3    LAMEA Cancer Immunotherapy Colorectal Cancer Market by Country
4.1.4    LAMEA Cancer Immunotherapy Melanoma Market by Country
4.1.5    LAMEA Cancer Immunotherapy Prostate Cancer Market by Country
4.1.6    LAMEA Cancer Immunotherapy Head & Neck Cancer Market by Country
4.1.7    LAMEA Other Application Cancer Immunotherapy Market by Country
Chapter 5.    LAMEA Cancer Immunotherapy Market by End User
5.1.1    LAMEA Hospitals Cancer Immunotherapy Market by Country
5.1.2    LAMEA Clinics Cancer Immunotherapy Market by Country
5.1.3    LAMEA Other End User Cancer Immunotherapy Market by Country
Chapter 6.    LAMEA Cancer Immunotherapy Market by Country
6.1    Brazil Cancer Immunotherapy Market
6.1.1    Brazil Cancer Immunotherapy Market by Technology
6.1.2    Brazil Cancer Immunotherapy Market by Application
6.1.3    Brazil Cancer Immunotherapy Market by End User
6.2    Argentina Cancer Immunotherapy Market
6.2.1    Argentina Cancer Immunotherapy Market by Technology
6.2.2    Argentina Cancer Immunotherapy Market by Application
6.2.3    Argentina Cancer Immunotherapy Market by End User
6.3    UAE Cancer Immunotherapy Market
6.3.1    UAE Cancer Immunotherapy Market by Technology
6.3.2    UAE Cancer Immunotherapy Market by Application
6.3.3    UAE Cancer Immunotherapy Market by End User
6.4    Saudi Arabia Cancer Immunotherapy Market
6.4.1    Saudi Arabia Cancer Immunotherapy Market by Technology
6.4.2    Saudi Arabia Cancer Immunotherapy Market by Application
6.4.3    Saudi Arabia Cancer Immunotherapy Market by End User
6.5    South Africa Cancer Immunotherapy Market
6.5.1    South Africa Cancer Immunotherapy Market by Technology
6.5.2    South Africa Cancer Immunotherapy Market by Application
6.5.3    South Africa Cancer Immunotherapy Market by End User
6.6    Nigeria Cancer Immunotherapy Market
6.6.1    Nigeria Cancer Immunotherapy Market by Technology
6.6.2    Nigeria Cancer Immunotherapy Market by Application
6.6.3    Nigeria Cancer Immunotherapy Market by End User
6.7    Rest of LAMEA Cancer Immunotherapy Market
6.7.1    Rest of LAMEA Cancer Immunotherapy Market by Technology
6.7.2    Rest of LAMEA Cancer Immunotherapy Market by Application
6.7.3    Rest of LAMEA Cancer Immunotherapy Market by End User
Chapter 7.    Company Profiles
7.1    Amgen Inc.
7.1.1    Company Overview
7.1.2    Financial Analysis
7.1.3    Segmental & Regional Analysis
7.1.4    Research and Development Expense
7.2    Merck & Company, Inc.
7.2.1    Company Overview
7.2.2    Financial Analysis
7.2.3    Regional and Segmental Analysis
7.2.4    Research & Development
7.3    Pfizer Inc.
7.3.1    Company Overview
7.3.2    Financial Analysis
7.3.3    Segmental &Regional Analysis
7.3.4    Revenue analysis by Region
7.3.5    Research and Development
7.4    Immunomedics Inc.
7.4.1    Company Overview
7.4.2    Financial Analysis
7.4.3    Revenue Analysis by Region
7.4.4    Research and Development
7.5    Astrazeneca Plc.
7.5.1    Company Overview
7.5.2    Financial Analysis
7.5.3    Segmental analysis
7.5.4    Research & Development
7.6    F. Hoffmann-La Roche Ltd.
7.6.1    Company Overview
7.6.2    Financial Analysis
7.6.3    Revenue & Segment analysis
7.6.4    Research and Development
7.7    Eli Lilly and Company
7.7.1    Company Overview
7.7.2    Financial Analysis
7.7.3    Segmental and Regional Analysis
7.7.4    Research & Development Expense
7.8    Novartis AG
7.8.1    Company Overview
7.8.2    Financial Analysis
7.8.3    Segmental and Regional Analysis
7.8.4    Research & Development Expense
7.9    Bristol-Myers Squibb Company
7.9.1    Company Overview
7.1    Bayer AG
7.10.1    Company Overview
7.10.2    Financial Analysis
7.10.3    Segmental and Regional Analysis
7.10.4    Research & Development Expense

TABLE 1    LAMEA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 2    LAMEA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 3    LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 4    LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 5    LAMEA MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 6    LAMEA MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 7    LAMEA CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 8    LAMEA CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 9    LAMEA OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 10    LAMEA OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 11    LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 12    LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 13    LAMEA CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 14    LAMEA CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 15    LAMEA CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 16    LAMEA CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 17    LAMEA CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 18    LAMEA CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 19    LAMEA CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 20    LAMEA CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 21    LAMEA CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 22    LAMEA CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 23    LAMEA CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 24    LAMEA CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 25    LAMEA OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 26    LAMEA OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 27    LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 28    LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 29    LAMEA HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 30    LAMEA HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 31    LAMEA CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 32    LAMEA CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 33    LAMEA OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 34    LAMEA OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 35    LAMEA CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 36    LAMEA CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 37    BRAZIL CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 38    BRAZIL CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 39    BRAZIL CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 40    BRAZIL CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 41    BRAZIL CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 42    BRAZIL CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 43    BRAZIL CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 44    BRAZIL CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 45    ARGENTINA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 46    ARGENTINA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 47    ARGENTINA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 48    ARGENTINA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 49    ARGENTINA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 50    ARGENTINA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 51    ARGENTINA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 52    ARGENTINA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 53    UAE CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 54    UAE CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 55    UAE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 56    UAE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 57    UAE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 58    UAE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 59    UAE CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 60    UAE CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 61    SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 62    SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 63    SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 64    SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 65    SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 66    SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 67    SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 68    SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 69    SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 70    SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 71    SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 72    SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 73    SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 74    SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 75    SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 76    SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 77    NIGERIA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 78    NIGERIA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 79    NIGERIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 80    NIGERIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 81    NIGERIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 82    NIGERIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 83    NIGERIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 84    NIGERIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 85    REST OF LAMEA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 86    REST OF LAMEA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 87    REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 88    REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 89    REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 90    REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 91    REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 92    REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 93    KEY INFORMATION-AMGEN INC.
TABLE 94    KEY INFORMATION-MERCK & COMPANY INC.
TABLE 95    KEY INFORMATION- PFIZER INC.
TABLE 96    KEY INFORMATION- IMMUNOMEDICS INC.
TABLE 97    KEY INFORMATION- ASTRAZENECA PLC.
TABLE 98    KEY INFORMATION- F. HOFFMANN-LA ROCHE LTD.
TABLE 99    KEY INFORMATION – ELI LILLY AND COMPANY
TABLE 100    KEY INFORMATION – NOVARTIS AG
TABLE 101    KEY INFORMATION - BRISTOL-MYERS SQUIBB COMPANY
TABLE 102    KEY INFORMATION – BAYER AG